← Back to Search

Tetracycline Antibiotic

Doxycycline for Hereditary Hemorrhagic Telangiectasia (HHT) (HHT Trial)

Phase 2

Waitlist Available

Led By Marie E Faughnan, MD MSc FRCPC

Research Sponsored by Unity Health Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, week 12, week 18, week 24, week 30, week 36, week 42, week 48, week 60, week 66, week 72, week 78, week 84, week 96

Awards & highlights

HHT Trial Summary

This trial will investigate whether doxycycline can help treat recurrent nosebleeds in people with a hereditary disorder that causes abnormal blood vessel growth.

Who is the study for?

Adults over 18 with Hereditary Hemorrhagic Telangiectasia (HHT) who experience frequent nosebleeds and have specific HHT-related genetic mutations. Participants must not be pregnant, breastfeeding, planning to become pregnant, or have unstable illnesses or allergies to doxycycline.Check my eligibility

What is being tested?

The trial is testing if doxycycline can reduce the severity of nosebleeds in HHT patients compared to a placebo. It's a Phase II study where participants will take either doxycycline or a placebo for six months and then switch treatments.See study design

What are the potential side effects?

Doxycycline may cause side effects such as digestive issues, skin sensitivity to sunlight, teeth discoloration, and possibly affect liver enzymes or kidney function.

HHT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, week 12, week 18, week 24, week 30, week 36, week 42, week 48, week 60, week 66, week 72, week 78, week 84, week 96

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, week 12, week 18, week 24, week 30, week 36, week 42, week 48, week 60, week 66, week 72, week 78, week 84, week 96

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 12, week 18, week 24, week 30, week 36, week 42, week 48, week 60, week 66, week 72, week 78, week 84, week 96 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Epistaxis

Secondary outcome measures

Change in epistaxis severity score (ESS)

Elucidate the mechanisms of action of doxycycline using tissue sample

Measures related to chronic bleeding by a change from baseline

+2 more

HHT Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: doxycycline HyclateActive Control1 Intervention

subjects will be treated with a 6-month course of doxycycline oral capsule at a dose of 100mg twice daily

Group II: PlaceboPlacebo Group1 Intervention

subjects will be given a placebo oral capsule twice daily for 6-months

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of PittsburghOTHER

1,719 Previous Clinical Trials

16,342,311 Total Patients Enrolled

Duke UniversityOTHER

2,359 Previous Clinical Trials

3,420,192 Total Patients Enrolled

Sunnybrook Health Sciences CentreOTHER

656 Previous Clinical Trials

1,550,647 Total Patients Enrolled

Media Library

Doxycycline Hyclate (Tetracycline Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT03397004 — Phase 2

Osler-Weber-Rendu Syndrome Research Study Groups: doxycycline Hyclate, Placebo

Osler-Weber-Rendu Syndrome Clinical Trial 2023: Doxycycline Hyclate Highlights & Side Effects. Trial Name: NCT03397004 — Phase 2

Doxycycline Hyclate (Tetracycline Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03397004 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are invited to take part in this experiment?

"At the present moment, this clinical trial isn't actively accepting participants. The research was uploaded on September 12th 2018 and last updated February 8th 2022. If you are seeking another study to participate in, there are 20 trials related to spider veins that have open recruitment periods and 39 studies involving doxycycline Hyclate with vacancy for volunteers."

Answered by AI

What adverse effects may occur from taking doxycycline Hyclate?

"The safety of doxycycline Hyclate is quantified as a 2 on the 1 to 3 scale; this reflects that while there are data indicating it's safe, none verifying its efficacy has been collected."

Answered by AI

Is the opportunity to apply for this experiment still available?

"Unfortunately, the recruitment period for this trial has ended. Initially posted in September 2018, and most recently updated on February 8th 2022; applicants are no longer being accepted at this time. However, there are currently 20 studies recruiting participants with spider veins and 39 trials seeking participation involving doxycycline Hyclate."

Answered by AI

In what ways is doxycycline Hyclate typically utilized therapeutically?

"Doxycycline Hyclate is commonly prescribed for the management of severe acne. It has also been used to combat a variety of other conditions, including chlamydia, trachoma and klebsiella infections."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Doxycycline for Hereditary Hemorrhagic Telangiectasia

2018. "Doxycycline for Hereditary Hemorrhagic Telangiectasia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03397004.

All > Hereditary Angioedema